Spanish R&D: still open for business
Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous…
Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous…
“The IMS Health figures show around three to four percent growth in the marketplace,” remarks Raymund Azurin, chief executive of Zuellig Pharma Philippines, “but we are now at a…
In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s pharmaceutical market, a tremendous feat considering laws for generics had only been implemented a few…
“Over the past twenty years, we have seen a drastic change in the socio-economic climate of the Gulf region and neighboring countries. There has been considerable growth in terms of…
When PharmaBoardroom came to Portugal in 2007, price cuts, payment delays and changes to the health system with each successive government were but the first indications for the pharmaceutical…
Before the introduction of universal healthcare (UHC), most major private hospitals in the Philippines had to rely on imported products. With the MNCs showing only limited interest in small volumes,…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
Canada operates a single-payer healthcare system in which the majority of services are provided by private entities, which are paid for at the provincial level. The Canada Health Act…
Between Portugal’s two main distribution channels of hospitals and pharmacies, hospitals have suffered in particular. As the pharmaceutical industry’s largest customer, it has been critical for government to work with…
The inclusion of healthcare as a priority on the presidential agenda has led to knock-on consequences that are being felt across the healthcare value chain in the Philippines. Universal…
Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D throughout its vast geography. “Science powers commerce,” Canadian Prime Minister…
In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to…
See our Cookie Privacy Policy Here
